New Triple-Action pill enters human testing in fight against tough cancers
Disease control
Recruiting now
This is a first-in-human study to test the safety and find the right dose of a new oral drug, OKN4395, for people with advanced solid tumors. The trial will give the drug alone and combined with an existing immunotherapy (pembrolizumab) to about 166 participants with cancers like…
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC